Allergan acquires double-chin treatment manufacturer, Kythera, for $2.1 billion; Valeant eyes acquisition of Egyptian drugmaker; worldwide drug sales could reach $1 trillion by 2020
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix